GARLINSY
Live / Applied — Non-final action mailed (as of 25 Jun 2026)
What this means for you
Not registered yet, but its 13 May 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99821567
- Mark type
- Design + words
- Filed
- 13 May 2026
- Attorney of record
- Eric R. Moran
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; insulin; insulin glargine; insulin analog; anti-diabetics; pharmaceuticals for treating diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical products for treating diabetes; pharmaceutical preparations, namely, injectable insulin; pharmaceutical preparations, namely, injectable insulin glargine; pharmaceutical preparations, namely, injectable insulin analog; pharmaceutical preparations, namely, injectable anti-diabetics; injectable pharmaceutical preparations for treating diabetes; injectable pharmaceutical products for treating diabetes; injectors sold filled with insulin; insulin injectors sold filled with insulin glargine; insulin injectors sold filled with insulin analog; injectors sold filled with pharmaceuticals for treating diabetes; injectors sold filled with anti-diabetics
Owner
- Emerge Bioscience Pte. Ltd., Singapore, SG
Prosecution history
- 16 Sept 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 16 Sept 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 25 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Jun 2026 — NON-FINAL ACTION E-MAILED
- 25 Jun 2026 — NON-FINAL ACTION WRITTEN
- 25 Jun 2026 — ASSIGNED TO EXAMINER
- 24 Jun 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 24 Jun 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 May 2026 — APPLICATION FILING RECEIPT MAILED
- 13 May 2026 — NEW APPLICATION ENTERED